(Q37841542)

24 August 2017

1 reference

title

The role of dopamine agonists in the treatment of depression in patients with Parkinson's disease: a systematic review (English)

1 reference

24 August 2017

0 references

0 references

1 reference

1 reference

Albert F G Leentjens

1

1 reference

24 August 2017

publication date

1 February 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

71

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

273-286

1 reference

https://scigraph.springernature.com/pub.10.2165/11585380-000000000-00000

24 August 2017

exact match

0 references

cites work

The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

Treatment of Parkinson's disease: a survey of patients and neurologists

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

Pramipexole for depression and motor symptoms in Parkinson's disease: can we kill two birds with one stone?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

A systematic review of prevalence studies of depression in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

Occurrence risk and structure of depression in Parkinson disease with and without dementia: results from the GEPAD Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

Risk factors for depression in Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

Anxious and depressive symptoms in Parkinson's disease: the French cross-sectionnal DoPaMiP study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

Depression and disability in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

The occurrence of depression in Parkinson's disease. A community-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

The association between motor subtypes and psychopathology in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

Depression is associated with impairment of ADL, not motor function in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

The impact of depressive symptoms in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

What contributes to quality of life in patients with Parkinson's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

The correlation of depression with functional activity in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

Neuropsychological impairment in Parkinson's disease with and without depression

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

Relationship between depression and cognitive dysfunctions in Parkinson's disease without dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

Measuring the impact of Parkinson's disease with the Parkinson's Disease Quality of Life questionnaire.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

Factors impacting on quality of life in Parkinson's disease: results from an international survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

The impact of antidepressant treatment on cognitive functioning in depressed patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

Motor changes during sertraline treatment in depressed patients with Parkinson's disease*.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

Non-recognition of depression and other non-motor symptoms in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

Pramipexole in Parkinson disease. Results of a treatment observation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

Pramipexole in routine clinical practice: a prospective observational trial in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on Parkinsonian tremor

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

The association of dopamine agonists with daytime sleepiness, sleep problems and quality of life in patients with Parkinson's disease--a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

[Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy]

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

Effects of ropinirole on nonmotor symptoms of Parkinson disease: a prospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

Nonmotor symptoms in de novo Parkinson disease before and after dopaminergic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

Provisional diagnostic criteria for depression in Parkinson's disease: report of an NINDS/NIMH Work Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

Depression rating scales in Parkinson's disease: critique and recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

Comparative Review of Dopamine Receptor Agonists in Parkinson's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

Is the mesocortical dopaminergic system involved in Parkinson disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

Staging of brain pathology related to sporadic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

Antidepressant studies in Parkinson's disease: a review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

SSRIs in the treatment of depression in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

Onset of action of antidepressants: results of different analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

A controlled trial of antidepressants in patients with Parkinson disease and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585380-000000000-00000

Association between the dopamine D3 receptor gene locus (DRD3) and unipolar affective disorder

21 January 2018

1 reference

12 December 2020

Activity and acceptability of piribedil in Parkinson's disease: a multicentre study

1 reference

12 December 2020

Antidepressants for major depressive disorder in patients with a co-morbid axis-III disorder: a meta-analysis of patient characteristics and placebo response rates in randomized controlled trials

1 reference

12 December 2020

Depression in Parkinson's disease

1 reference

12 December 2020

Use of the dopamine receptor agonist Mirapex in the treatment of Parkinson's disease

1 reference

12 December 2020

1 reference

12 December 2020

Left-sided Parkinson's disease is associated with greater anxiety and depression.

1 reference

12 December 2020

Mental symptoms in Parkinson's disease are important contributors to caregiver distress.

1 reference

12 December 2020

Markers for depression in Parkinson's disease

1 reference

12 December 2020

Dopamine and depression: A review of recent evidence. II. Theoretical approaches

1 reference

12 December 2020

Depression in classic versus akinetic-rigid Parkinson's disease

1 reference

12 December 2020

Recognition and treatment of depression in Parkinson's disease

1 reference

12 December 2020

What contributes to depression in Parkinson's disease?

1 reference

12 December 2020

1 reference

12 December 2020

Piribedil therapy in Parkinson's disease. Use of the drug in the retard form

1 reference

12 December 2020

Cognitive-behavioral therapy for depression in Parkinson's disease: a pilot study

1 reference

12 December 2020

Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study

1 reference

12 December 2020

Antidepressant-like effect of D(2/3) receptor-, but not D(4) receptor-activation in the rat forced swim test

1 reference

12 December 2020

10.2165/11585380-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

24 August 2017

1013629560

0 references

1 reference